PRNewswire (Fri, 26-Dec 12:00 PM ET)
Globe Newswire (Tue, 23-Dec 8:00 AM ET)
Class Action Lawsuit Puts Spotlight on Quantum BioPharma and Its Strategic Assets
Market Chameleon (Mon, 22-Dec 4:53 AM ET)
ACCESS Newswire (Mon, 22-Dec 9:00 AM ET)
Globe Newswire (Mon, 1-Dec 7:00 AM ET)
Globe Newswire (Fri, 28-Nov 9:30 AM ET)
Quantum BioPharma Spotlights $700M Lawsuit and Stock Spoofing Allegations in National TV Exposé
Market Chameleon (Fri, 28-Nov 2:28 AM ET)
Globe Newswire (Thu, 27-Nov 4:00 PM ET)
QNTM Draws Spotlight as $700 Million Market Manipulation Lawsuit Gains National Attention
Market Chameleon (Wed, 26-Nov 6:06 AM ET)
Globe Newswire (Tue, 25-Nov 4:00 PM ET)
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the NASDAQ stock market under the symbol QNTM.
As of December 26, 2025, QNTM stock price declined to $8.30 with 53,831 million shares trading.
QNTM has a beta of 1.61, meaning it tends to be more sensitive to market movements. QNTM has a correlation of 0.02 to the broad based SPY ETF.
QNTM has a market cap of $31.90 million. This is considered a Sub-Micro Cap stock.
Last quarter Quantum Biopharma Ltd. - Class B Subordinate Voting Shares reported $0 in Revenue and -$1.25 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.17.
QNTM has outperformed the market in the last year with a return of +137.8%, while the SPY ETF gained +16.0%. However, in the most recent history, QNTM shares have underperformed the stock market with its stock returning -49.1% in the last 3 month period and -11.5% for the last 2 week period, while SPY has returned +4.6% and +1.5%, respectively.
QNTM support price is $7.63 and resistance is $9.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QNTM shares will trade within this expected range on the day.
